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ABSTRACT
O b je c t i v e :  Anti-proteinuric effects of angiotensin 
converting enzyme inhibitors (ACE-I) and 
angiotensin receptor blockers (ARB) have been 
established in various renal diseases. However, 
the effects of ACE-I and ARB on the permeability 
of peritoneal membrane are unknown and the 
effect of ACE-I and ARB use on peritoneal 
permeability in patients undergoing continuous 
ambulatory peritoneal dialysis has not been 
studied.
M e t h o d s :  Fifty non-diabetic patients with high 
peritoneal permeability, who had been on a 
regular peritoneal dialysis (PD) treatment for at 
least one year, were included in the study. The 
patients were prospectively randomized either 
fosinopril 10 mg/day p.o (n=25) (group 1) or 
valsartan 80 mg/day p.o (n=25) (group 2) for 12 
months. All patients received standard 35- 
cal/kg/day diets with 1,2-g/kg/day protein intake 
and strict salt restriction. All patients were on 
standard PD program (2 L; 1.36%, 4
exchanges/day). Annual mean serum albumin 
level, calculated from the monthly serum albumin 
level and peritoneal albumin values obtained 
from the dialysate after 8 hours, dwell on two 
occasions 6 months apart were measured twice 
yearly.
R e s u l t s :  A significant increase in the serum 
albumin values, (3.68±0.56 g/dl vs. 3.94±0.46 
g/dl, p<0.0001) a significant decrease in 
peritoneal fluid albumin values (9.06±2.65 g/dl vs. 
7.08±1.43 g/dl, p<0.01) were observed in the 
ACE-I group following the treatment. While no 
significant change (3.75±0.48 g/dl vs. 3.87±0.37 
g/dl, p>0.05) was observed in the serum albumin 
values, a significant decrease (8.62±3.87 g/dl vs. 
5.84±2.94 g/dl, p<0.01) was obtained in 
peritoneal fluid albumin values for the ARB group.
C o n c l u s i o n :  At the end of the study a significant 
decrease was observed in the peritoneal protein 
values for patients on ACE-I and ARB.
K e y  W o rd s : Peritoneal dialysis, Angiotensin 
converting enzyme inhibitor, Angiotensin 
receptor blocker and albumin
IN T R O D U C T IO N
Abnormal excretion of protein in the urine has 
long been recognized as a marker of glomerular 
injury (1-3). Peritoneal protein leakage is the 
most common cause of functional transport 
abnormality from continuous ambulatory 
peritoneal dialysis (CAPD) in long-term
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peritoneal dialysis. During CAPD, various 
morphological changes take place in the 
peritoneum, including mesothelial denudation, 
interstitial fibrosis, neovascularization, and 
vascular alterations. Angiotensin-ll (ANG-II) 
plays a role in stimulating macrophages and 
fibroblast-like cells to secrete TGFp-1. A 
perivascular/interstitial fibrosis, for instance, 
accompanies chronic elevation in either 
circulating ANG-II or aldosterone (4) and, in case 
of ANG II, occurs in response to abnormal 
vascular permeability and the escape of 
macromolecules (5). These effects of ANG II in 
CAPD patients can be prevented by the same 
method described above for clinical studies, and 
peritoneal protein loss may be reduced.
M ATER IA LS A N D  M E TH O D S
High and high-average transporter patients who 
have been on regular CAPD treatment for at least 
one year, who have not used any non-diabetic, 
essential amino acid and whose level of blood 
pressure was between 140-160/90-100 mmHg 
and daily urinary output between 50-300 cc were 
included in this study. Patients were selected by 
an open randomized method. Twenty- five 
patients were selected for fosinopril 10 mg, and 
25 for valsartan 80 mg treatment. Before 
treatment, annual mean peritoneal albumin 
values were obtained for those patients on a diet 
of 35 cl/kg/day: (45% carbohydrate, 20% fat, 30% 
protein) and Standard PD program (2 L; 4 
exchanges/day). Among the patients who used 
their medications for one year, who had an 
infection with a CRP level above 5 mg/l, who were 
identified to have additional volume during the 
visits and who could not comply with their 
medication and diet, and those who had to leave 
the standard dialysis program were excluded from 
the study. At the end of a year, while 23 of the 
patients on fosinopril completed the study, only 13 
of the patients on valsartan did so. Serum and 
peritoneal albumin values were obtained by the 
method of spectrophotometry.
Statistical analysis: GraphPad was prepared by 
the Prisma V.3 packet program. Besides, the 
descriptive statistical methods (means, standard 
deviations) used in analysing data, a separate t 
test was used for comparisons between groups, 
and a paired t test was used for repeating
measures of the groups. The results were 
evaluated for the significance level of p<0.05 with 
a confidence interval of 95%.
RESULTS
Twenty-two patients from the ACE-I group and 
13 patients from ARB group completed the study. 
Three patients from the ACE-I group were 
excluded from the study, two for lack of 
compliance and one because of a peritonitis 
attack. In ARB group, 12 patients were excluded 
from the study; 6 for lack of compliance, 1 for 
active pulmonery tuberculosis, 2 for peritonitis, 1 
for dental infection, 1 for insufficient dialysis due 
to leakage and for instrumental peritoneal 
dialysis, 1 for continuing additional volume. Table 
I demonstrates age and Body Mass Index (BMI) 
for the remaining patients.
Table I: Age and BMI comparison of each group.
ARB
(n=13)
ACE
n=(22)
t P
Age 44.38+13.65 47.59±14.47
0.64
>0.05
BMI 25.08±4.96 23.64+3.85 0.96 >0.05
BMI: Body Mass Index
While no significant changes (3.75±0.48 g/dl vs. 
3.87±0.37 g/dl, p>0.05) were observed in the 
serum albumin values, a significant decrease 
(8.62±3.87 g/dl vs. 5.84±2.94 g/dl, p<0.01) was 
obtained in peritoneal albumin values in the ARB 
group. After treatment, a significant increase 
(3.68±0.56 g/dl vs. 3.9410.46 g/dl, p<0.0001) in 
the serum albumin values and a significant 
decrease in the peritoneal albumin levels 
(9.0612.65 g/dl vs. 7.0811.43 g/dl, p<0.01) were 
observed in the ACE-I group. (Figs 1-2)
F i g . l : Comparative values of serum albumin in both treatment 
groups before and after treatment.
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F ig .2 :  Comparative values of peritoneal albumin in both 
treatment groups before and after treatment.
The rate of exchange between pre and post­
treatment serum albumin values In the ACE-I 
group was significantly higher than in that of the 
ARB group. In contrast, the rate of exchange 
between pre and post-treatment peritoneal 
albumin values in the ACE-I group was not 
significantly different than that of the ARB group 
(Table II).
Table II: Serum and peritoneal albumin exchange rates in 
both treatment groups
ARB
(n=13)
ACE I
n=(22)
t P
Serum
Albumin 3 .13±6.33 7.34±5.31 -2.08 <0.05
Peritoneal
Albumin 26.92±26.06 16.64+28.18 0.98 >0.05
D IS C U S S IO N
Remarkable antiproteinuric effects of ACE-I and 
ARBs, leading agents in antihypertensive 
treatment for the last century have been 
demonstrated in various clinical and 
experimental studies regardless of their blood 
pressure lowering effects (3,6-10). These agents 
have been used to prevent the vasoactive, 
proliferative, pro-oxidative, and permeative 
pathophysiological effects of ANGII treatment 
such as vasoconstriction, aldosteron release, 
sodium retention, hypertrophy in renal mesengial 
and tubulointerstitial cells, collagen 
accumulation, cardiac hypertrophy in 
cardiomiocytes and fibroblast and cardiac 
collagen accumulation, increased secretion by 
endothelium, increased release of vasopressin, 
facilitated sympathetic-adrenergic activation, 
facilitated supernoxide formation, increased level
of plasminogen activator inhibitor-1, and 
accelerated gene expression (11,12).
A variety of morphological changes in the 
peritoneal membrane develop by similar 
mechanisms in patients undergoing peritoneal 
dialysis and lead to increased membrane 
permeability and thus to increased protein 
leakage into the peritoneal fluid. This is an 
unwanted situation for patients undergoing 
CAPD. The present study was conducted based 
on the idea that protein leakage of the peritoneal 
membrane could be decreased by use of ACEI 
and ARB regardless of their antihypertensive 
effects. At the end of the study a significant 
decreased was observe in the values for 
peritoneal protein.
At the end of the study, a significant decrease 
was observed in the peritoneal protein values in 
patients on ACE-I and ARB. While there was a 
significant increase in serum albumin values in 
the ACE-I group, a respective increase in the 
ARB group was not found to be significant. The 
large numbers of dropouts in ARB group and 
relatively smaller number of patients compared to 
the ACE-I group were considered to be 
responsible for this result.
In conclusion, ACE-I and ARB use in CAPD 
patients led to decreased loss of albumin into 
peritoneal fluid. The increase observed in the 
values of serum albumin in the ARB group failed 
to reach a significant level due to the decreased 
number of patients in this group. These results 
need to be supported by clinical and experimental 
studies involving a large number of patients.
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